Drug susceptibility and resistance mutations after first-line failure in resource limited settings (Q34106181)

31 July 2017

title

Drug susceptibility and resistance mutations after first-line failure in resource limited settings (English)

1 reference

Nagalingeswaran Kumarasamy

31 July 2017

author

7

object named as

Nagalingeswaran Kumarasamy

1 reference

31 July 2017

3

Heather Ribaudo

1 reference

31 July 2017

Carole L Wallis

1

1 reference

31 July 2017

Evgenia Aga

2

1 reference

31 July 2017

Shanmugam Saravanan

4

1 reference

31 July 2017

Michael Norton

5

1 reference

31 July 2017

Wendy Stevens

6

1 reference

31 July 2017

John Bartlett

8

1 reference

31 July 2017

David Katzenstein

9

1 reference

31 July 2017

A5230 team

10

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 May 2014

1 reference

Clinical Infectious Diseases

31 July 2017

published in

1 reference

31 July 2017

volume

59

1 reference

31 July 2017

issue

5

1 reference

31 July 2017

page(s)

706-715

1 reference

Increased risk of Q151M and K65R mutations in patients failing stavudine-containing first-line antiretroviral therapy in Cambodia

31 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: programmatic implications for countries phasing out stavudine

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Update of the drug resistance mutations in HIV-1: March 2013.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Surveillance of transmitted HIV-1 drug resistance in Gauteng and KwaZulu-Natal Provinces, South Africa, 2005-2009.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Affordable in-house antiretroviral drug resistance assay with good performance in non-subtype B HIV-1.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Assessing Resistance Costs of Antiretroviral Therapies via Measures of Future Drug Options

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Evolution and diversity of HIV-1 in Africa--a review.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Adverse effects of antiretroviral therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study

5 July 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU314

Varied patterns of HIV-1 drug resistance on failing first-line antiretroviral therapy in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU314

Accumulation of HIV drug resistance mutations in patients failing first-line antiretroviral treatment in South Africa

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU314

Structural analysis of reverse transcriptase mutations at codon 215 explains the predominance of T215Y over T215F in HIV-1 variants selected under antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU314

HIV-1 drug resistance at virological failure versus immunological failure among patients failing first-line antiretroviral therapy in a resource-limited setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU314

Effect of mutations at position E138 in HIV-1 reverse transcriptase on phenotypic susceptibility and virologic response to etravirine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU314

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU314

Will etravirine work in patients failing nonnucleoside reverse transcriptase inhibitor-based treatment in southern Africa?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCID%2FCIU314

Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4148601

Substitutions due to antiretroviral toxicity or contraindication in the first 3 years of antiretroviral therapy in a large South African cohort

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24795328

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/CID/CIU314

1 reference

31 July 2017

1 reference

31 July 2017

1 reference